Cardiovascular Benefits
In the SELECT trial, semaglutide lowered MACE risk in adults with established ASCVD and BMI ≥27 who did not have diabetes. GLP-1 receptor agonists reduced hospitalizations for heart failure by 11% in patients with diabetes. A meta-analysis…
1 sources - 4 claims
In the SELECT trial, semaglutide lowered MACE risk in adults with established ASCVD and BMI ≥27 who did not have diabetes. GLP-1 receptor agonists reduced hospitalizations for heart failure by 11% in patients with diabetes. A meta-analysis found that GLP-1 receptor agonists reduced major adverse cardiovascular events by 14% in patients with diabetes. Whether the cardiovascular benefits of GLP-1 medications are drug-direct effects or mediated by weight loss remains under active investigation.